文献速递细菌感染、耐药与抗菌药物医院感染防控

氟喹诺酮预防用药筛选出血液恶性肿瘤及造血干细胞移植患者对美罗培南不敏感的铜绿假单胞菌

Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients.
PubMed 文献 · Clin Infect Dis · 2019-01-01

该回顾性研究分析了7年间51例血液恶性肿瘤或造血干细胞移植患者中55次铜绿假单胞菌血流感染,发现氟喹诺酮预防用药期间突破性菌血症与美罗培南不敏感相关,且氟喹诺酮预防是美罗培南不敏感菌株感染的独立预测因素;全基因组测序显示所有美罗培南不敏感菌株均携带oprD失活突变,且外排泵抑制剂可降低其美罗培南MIC。

要点

  • 氟喹诺酮预防期间突破性铜绿假单胞菌菌血症与美罗培南不敏感相关。
  • 氟喹诺酮预防是美罗培南不敏感铜绿假单胞菌菌血症的独立预测因素。
  • 美罗培南不敏感菌株均伴oprD失活突变及外排泵活性增强。

核心结论

  • 在血液恶性肿瘤患者和造血干细胞移植受者中,氟喹诺酮预防用药与突破性美罗培南不敏感铜绿假单胞菌菌血症相关。

研究设计与样本

  • 回顾性评估7年期间单中心血液恶性肿瘤或造血干细胞移植患者中铜绿假单胞菌血流感染 episodes。
  • 共分析51例患者的55次铜绿假单胞菌菌血症。
  • 对部分分离株进行全基因组测序和外排泵活性表型评估。

主要发现

  • 氟喹诺酮预防期间发生的突破性菌血症与美罗培南不敏感相关,但与抗假单胞菌β-内酰胺类或氨基糖苷类不敏感无关。
  • 接受氟喹诺酮预防独立预测美罗培南不敏感分离株菌血症。
  • 所有经全基因组测序分析的美罗培南不敏感分离株均含oprD失活突变。
  • 所有检测的美罗培南不敏感分离株在外排泵抑制剂存在下美罗培南最低抑菌浓度降低。
  • 基于全基因组测序的系统发育分析显示来自不同患者的多个紧密相关分离株簇。

临床怎么用

  • 对接受氟喹诺酮预防的血液恶性肿瘤或造血干细胞移植患者,出现突破性铜绿假单胞菌菌血症时应考虑美罗培南不敏感可能。

局限性

  • 回顾性单中心研究,样本量有限(55次菌血症)。
  • 原文未报告氟喹诺酮预防与美罗培南不敏感关联的具体效应值及置信区间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In Pseudomonas aeruginosa, fluoroquinolone exposure promotes resistance to carbapenems through upregulation of efflux pumps and transcriptional downregulation of the porin OprD. Evidence of this effect among hematologic malignancy (HM) patients or hematopoietic cell transplant (HCT) recipients receiving fluoroquinolone prophylaxis for neutropenia is lacking. METHODS: We retrospectively evaluated episodes of P. aeruginosa bloodstream infections in HM patients or HCT recipients over a 7-year period at our institution. We determined the association of fluoroquinolone prophylaxis at the time of infection with meropenem susceptibility of P. aeruginosa breakthrough isolates and risk factors for meropenem nonsusceptibility. Whole-genome sequencing (WGS) and phenotypic assessments of meropenem efflux pump activity were performed on select isolates to determine the mechanisms of meropenem resistance. RESULTS: We analyzed 55 episodes of P. aeruginosa bacteremia among 51 patients. Breakthrough bacteremia while on fluoroquinolone prophylaxis was associated with nonsusceptibility to meropenem, but not to antipseudomonal β-lactams or aminoglycosides. The receipt of fluoroquinolone prophylaxis was independently predictive of bacteremia with a meropenem-nonsusceptible isolate. All meropenem-nonsusceptible isolates analyzed by WGS contained oprD inactivating mutations, and all meropenem-nonsusceptible isolates tested demonstrated reductions in the meropenem minimum inhibitory concentration in the presence of an efflux pump inhibitor. A phylogenetic analysis based on WGS revealed several clusters of closely related isolates from different patients. CONCLUSIONS: Fluoroquinolone prophylaxis in HM patients and HCT recipients is associated with breakthrough bacteremia with meropenem-nonsusceptible P. aeruginosa strains, likely due to both mutations increasing efflux pump activity and the epidemiology of P. aeruginosa bloodstream infections in our patient population.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hakki M, Humphries RM, Hemarajata P, et al. Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients. Clin Infect Dis. 2019. PMID: 30256922. doi:10.1093/cid/ciy825

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。